HPGC Renmintongtai Pharmaceutical Corporation (SHA:600829)
China · Delayed Price · Currency is CNY 11.29
+0.18 (1.62%)
Feb 3, 2026, 3:00 PM CST
SHA:600829 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 10,175 | 10,007 | 10,349 | 9,598 | 9,277 | 7,973 |
Other Revenue | 41.1 | 41.1 | 40.7 | 43.11 | 37.82 | 31.94 |
| 10,216 | 10,048 | 10,390 | 9,641 | 9,315 | 8,005 | |
Revenue Growth (YoY) | -0.26% | -3.29% | 7.77% | 3.50% | 16.36% | -4.17% |
Cost of Revenue | 9,410 | 9,190 | 9,404 | 8,734 | 8,331 | 7,102 |
Gross Profit | 806.55 | 858.46 | 986.12 | 907.13 | 984.54 | 903.51 |
Selling, General & Admin | 524.42 | 506.23 | 519.16 | 506.2 | 544.46 | 622.87 |
Other Operating Expenses | 36.01 | 33.13 | 30.43 | 29 | 17.81 | 17.37 |
Operating Expenses | 609.6 | 558.53 | 574.43 | 524.12 | 571.43 | 650.76 |
Operating Income | 196.95 | 299.93 | 411.68 | 383.01 | 413.11 | 252.75 |
Interest Expense | -28.87 | -28.29 | -27.23 | -44.42 | -50.32 | -30.75 |
Interest & Investment Income | 4.01 | 21.65 | 17.82 | 13.34 | 5.94 | 6.03 |
Other Non Operating Income (Expenses) | -7.22 | -7.47 | -9.11 | -11.9 | -5.8 | -5.4 |
EBT Excluding Unusual Items | 164.87 | 285.83 | 393.16 | 340.02 | 362.93 | 222.64 |
Gain (Loss) on Sale of Assets | -0.13 | 0.23 | -0.35 | -0.41 | 0.05 | -0.11 |
Asset Writedown | -2.14 | -2.14 | -0.81 | -0.25 | -1.92 | -1.74 |
Legal Settlements | - | - | - | - | -0.29 | - |
Other Unusual Items | 6.62 | 5.15 | 1.38 | 6.2 | -2.16 | -1.09 |
Pretax Income | 169.22 | 289.06 | 393.39 | 345.56 | 358.6 | 219.7 |
Income Tax Expense | 50.07 | 75.79 | 101.14 | 81.04 | 82.09 | 74.74 |
Earnings From Continuing Operations | 119.14 | 213.27 | 292.25 | 264.51 | 276.51 | 144.96 |
Minority Interest in Earnings | -0 | 0 | -0.09 | -0.03 | 0.78 | 0.31 |
Net Income | 119.14 | 213.27 | 292.16 | 264.48 | 277.3 | 145.26 |
Net Income to Common | 119.14 | 213.27 | 292.16 | 264.48 | 277.3 | 145.26 |
Net Income Growth | -53.75% | -27.00% | 10.47% | -4.62% | 90.89% | -45.66% |
Shares Outstanding (Basic) | 580 | 580 | 580 | 580 | 580 | 581 |
Shares Outstanding (Diluted) | 580 | 580 | 580 | 580 | 580 | 581 |
Shares Change (YoY) | -0.02% | -0.01% | 0.01% | -0.00% | -0.20% | 0.20% |
EPS (Basic) | 0.21 | 0.37 | 0.50 | 0.46 | 0.48 | 0.25 |
EPS (Diluted) | 0.21 | 0.37 | 0.50 | 0.46 | 0.48 | 0.25 |
EPS Growth | -53.74% | -27.00% | 10.46% | -4.62% | 91.28% | -45.77% |
Free Cash Flow | 32.15 | 107.39 | 309.5 | 300.91 | -245.24 | -23.19 |
Free Cash Flow Per Share | 0.06 | 0.18 | 0.53 | 0.52 | -0.42 | -0.04 |
Dividend Per Share | - | - | 0.144 | - | - | 0.120 |
Gross Margin | 7.90% | 8.54% | 9.49% | 9.41% | 10.57% | 11.29% |
Operating Margin | 1.93% | 2.99% | 3.96% | 3.97% | 4.44% | 3.16% |
Profit Margin | 1.17% | 2.12% | 2.81% | 2.74% | 2.98% | 1.81% |
Free Cash Flow Margin | 0.32% | 1.07% | 2.98% | 3.12% | -2.63% | -0.29% |
EBITDA | 215.4 | 319.08 | 431.76 | 403.9 | 436.37 | 277.66 |
EBITDA Margin | 2.11% | 3.17% | 4.16% | 4.19% | 4.68% | 3.47% |
D&A For EBITDA | 18.45 | 19.15 | 20.08 | 20.89 | 23.26 | 24.9 |
EBIT | 196.95 | 299.93 | 411.68 | 383.01 | 413.11 | 252.75 |
EBIT Margin | 1.93% | 2.99% | 3.96% | 3.97% | 4.44% | 3.16% |
Effective Tax Rate | 29.59% | 26.22% | 25.71% | 23.45% | 22.89% | 34.02% |
Revenue as Reported | 10,216 | 10,048 | 10,390 | 9,641 | 9,315 | 8,005 |
Advertising Expenses | - | 9.1 | 5.86 | 5.45 | 8.91 | 0.62 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.